GlassScriptPhysician profile
Bradley Michael Collins
NPI 1326533308
$6,027.47
in general payments reported to CMS, 2019-2025
24 companies · $2,486 in 2025
The $2,486 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $989 · 2024: $2,553 · 2025: $2,486.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,027.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,027.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,259.02 | 2023-2025 | Krystexxa, Enbrel, Tavneos |
| Abbvie INC. | $1,045.23 | 2023-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $1,024.16 | 2023-2025 | Tremfya, Simponi Aria, Remicade |
| Ucb, INC. | $490.93 | 2024-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $433.88 | 2023-2025 | |
| Lilly USA, LLC | $412.44 | 2023-2025 | Taltz |
| Sandoz INC. | $315.08 | 2023-2025 | Hyrimoz, Jubbonti |
| Astrazeneca Pharmaceuticals LP | $206.40 | 2023-2025 | Saphnelo |
| Pfizer INC. | $191.35 | 2024-2025 | |
| Aurinia Pharma U.S., INC. | $142.84 | 2023-2024 | Lupkynis |
| Radius Health, INC. | $97.82 | 2025 | Tymlos |
| E.R. Squibb & Sons, L.L.C. | $77.84 | 2025 | Orencia |
| Fresenius Kabi USA, LLC | $50.00 | 2023-2024 | Idacio |
| Glaxosmithkline, LLC. | $34.79 | 2023-2024 | Benlysta |
| Actelion Pharmaceuticals US, INC. | $34.24 | 2024 | Opsumit, Uptravi |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $31.90 | 2024 | Actemra |
| Mallinckrodt Hospital Products INC. | $30.38 | 2024 | Acthar |
| Horizon Therapeutics Plc | $26.66 | 2023 | Krystexxa |
| Kiniksa Pharmaceuticals, LTD. | $24.12 | 2023 | Arcalyst |
| Genzyme Corporation | $22.39 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $21.18 | 2024 | Arcalyst |
| Organon LLC | $21.13 | 2024 | |
| Alexion Pharmaceuticals, INC. | $19.66 | 2025 | Strensiq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.03 | 2024 | Ofev |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.